Harbour Energy (HBR) is targeting a shareholder return of 15% in 2026, driven by what the company describes as bumper cash flows from its operations. The North Sea-focused oil and gas producer
Novo Nordisk has appointed Omnicom as its agency of record for US media buying, bringing an end to a six-year partnership with WPP’s Wavemaker. Omnicom will take over management of Novo Nordisk’s
More
The U.S. Senate has confirmed two nominees to the National Labor Relations Board, reshaping the body’s political balance in a significant move for American labour policy. The confirmations, which took place on
More
Elise Holtzman, founder and CEO of The Lawyer’s Edge, has challenged one of the most enduring myths in the legal profession about rainmaking. The widely held belief that business development is an
More
Palantir Technologies (PLTR) shares climbed sharply after Bank of America issued an upbeat assessment of the data analytics company following a strong earnings report. The boost from a major Wall Street bank
More
AbbVie (ABBV) has reclaimed the number one position in pharmaceutical TV advertising after rival Johnson & Johnson (JNJ) briefly overtook it in June’s rankings. Skyrizi’s return to the top was driven by
More
The U.S. Securities and Exchange Commission announced the creation of a new Retail Fraud Working Group within its Division of Enforcement on July 7, 2026. The new unit signals a sharper institutional
More
After a series of defeats at the Supreme Court over birthright citizenship, Donald Trump issued executive orders claiming he had won the legal battles. Trump had bitterly complained about losing the birthright
More
Wall Street faces a pivotal test this week as fresh inflation data arrives at a moment when US stocks have been trading near record highs. Investors are watching closely to see whether
More
The FTSE 250 index has produced one of its most striking performers in recent memory, with one constituent stock adding another 12% in a single trading session. The gain comes on top
More
Injected weight loss treatments continue to dominate physician preferences, with Eli Lilly’s (LLY) Zepbound leading the field despite a wave of new oral obesity medications arriving on the market. A Spherix Global
More